Cynata Therapeutics Limited (AU:CYP)
ASX:CYP
Top Page
Cynata Therapeutics Limited
(Sydney:CYP)
Select Model
Select Model
Rating:56Neutral
Price Target:
AU$0.31
▲(6.55% Upside)
Action:ReiteratedDate:02/13/26
The score is held back primarily by weak financial performance (large ongoing losses and negative free cash flow despite some stabilization), while technicals provide meaningful support due to a clear uptrend and positive momentum. Valuation is neutral-to-weak because the negative P/E reflects loss-making operations and there is no dividend yield.
Positive Factors
Proprietary Cymerus iPSC‑derived MSC platform
Cymerus provides a durable technical moat: iPSC‑derived, allogeneic MSCs enable off‑the‑shelf manufacturing and potentially scalable, repeatable production. That structural capability supports partnership and commercialization strategies over the medium term.
Negative Factors
Persistent large operating and net losses
Consistently massive operating losses and extreme negative net margins show the company is not close to self‑sustaining profitability. Over months this continues to erode equity, necessitates external capital, and limits reinvestment in R&D or commercialization without dilutive funding or partner support.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Cymerus iPSC‑derived MSC platform
Cymerus provides a durable technical moat: iPSC‑derived, allogeneic MSCs enable off‑the‑shelf manufacturing and potentially scalable, repeatable production. That structural capability supports partnership and commercialization strategies over the medium term.
Read all positive factors
Cynata Therapeutics Limited (CYP) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$71.24M
Dividend YieldN/A
Average Volume (3M)233.82K
Price to Earnings (P/E)―
Beta (1Y)0.57
Revenue GrowthN/A
EPS Growth16.61%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding237,454,380
10 Day Avg. Volume170,513
30 Day Avg. Volume233,823
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)5.14
Price to Sales (P/S)16.31
P/FCF Ratio-3.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)AU$6.40M
Cynata Therapeutics Limited Business Overview & Revenue Model
Company Description
Cynata Therapeutics Limited (CYP) is an Australian biotechnology company focused on the development and commercialization of innovative stem cell therapies. The company specializes in Cymerus™, a proprietary technology for manufacturing mesenchyma...
How the Company Makes Money
Cynata Therapeutics primarily seeks to make money by developing its cell-therapy candidates and then monetizing them through (1) partnering/licensing deals with larger pharmaceutical or biotechnology companies and (2) potential future product comm...
Cynata Therapeutics Limited Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.89M | 2.32M | 1.65M | 7.77M | 1.55M |
| Gross Profit | 1.89M | 2.32M | 1.37M | 7.49M | 1.27M |
| EBITDA | -9.33M | -9.95M | -15.65M | -6.00M | -8.80M |
| Net Income | -9.39M | -9.74M | -14.28M | -5.45M | -7.69M |
Balance Sheet | |||||
| Total Assets | 7.20M | 8.39M | 18.99M | 26.55M | 29.97M |
| Cash, Cash Equivalents and Short-Term Investments | 5.05M | 6.21M | 16.17M | 23.80M | 26.72M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.22M | 1.17M | 2.26M | 2.59M | 1.60M |
| Stockholders Equity | 5.98M | 7.22M | 16.73M | 23.96M | 28.37M |
Cash Flow | |||||
| Free Cash Flow | -8.77M | -9.96M | -14.28M | -3.30M | -5.16M |
| Operating Cash Flow | -8.72M | -9.96M | -14.28M | -3.30M | -5.16M |
| Investing Cash Flow | -50.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 7.61M | 0.00 | 6.72M | 210.12K | 18.20M |
Cynata Therapeutics Limited Technical Analysis
Negative
0.29
Price Trends
0.34
Negative
0.31
Negative
0.25
Positive
Market Momentum
-0.01
Positive
42.50
Neutral
54.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CYP, the sentiment is Negative. The current price of 0.29 is below the 20-day moving average (MA) of 0.32, below the 50-day MA of 0.34, and above the 200-day MA of 0.25, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 42.50 is Neutral, neither overbought nor oversold. The STOCH value of 54.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CYP.
Cynata Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$71.24M | -7.57 | -179.37% | ― | ― | 16.61% | |
53 Neutral | AU$33.06M | -6.66 | -258.19% | ― | 306.88% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$197.36M | 27.58 | -15.96% | ― | -40.74% | -21.21% | |
43 Neutral | AU$18.13M | -3.69 | 2509.60% | ― | ― | -36.89% | |
42 Neutral | AU$55.73M | -5.28 | -62.49% | ― | ― | 10.78% | |
40 Underperform | AU$35.68M | -10.60 | -142.30% | ― | 110.44% | 35.90% |
* Healthcare Sector Average
AU:CYP
Cynata Therapeutics Limited
0.30
0.11
62.16%
AU:PTX
Prescient Therapeutics Limited
0.05
<0.01
12.77%
AU:SPL
Starpharma Holdings Limited
0.47
0.38
400.00%
AU:ADO
AnteoTech Ltd
0.01
0.00
0.00%
AU:NOX
Noxopharm Ltd.
0.06
-0.02
-27.16%
AU:AVE
Avecho Biotechnology Limited
0.01
0.00
0.00%
Cynata Therapeutics Limited Corporate Events
Cynata Narrows Half-Year Loss but Faces Going Concern Uncertainty
Feb 26, 2026
Cynata Therapeutics reported revenue and other income of $1.77 million for the half-year to 31 December 2025, down about 10% from the prior corresponding period, while its loss after tax narrowed by 27% to $2.66 million. Despite an auditor’s...
Cynata to Host Investor Webinar and Expand Online Engagement With Shareholders
Feb 3, 2026
Cynata Therapeutics has scheduled an investor webinar for 11:30am AEDT on 4 February 2026, to be hosted by CEO and Managing Director Dr Kilian Kelly, providing an opportunity for shareholders and the broader investment community to receive an upda...
Cynata Nears Key Data Readouts as Pivotal Cell Therapy Trials Advance
Jan 29, 2026
Cynata Therapeutics reported strong clinical and operational progress in the December 2025 quarter, highlighted by completion of final patient visits in its large Phase 3 SCUlpTOR osteoarthritis trial of CYP-004 and completion of patient enrolment...
Cynata Raises $1.2m via At-The-Market Facility to Support Cell Therapy Pipeline
Jan 23, 2026
Cynata Therapeutics has raised approximately $1.2 million in net proceeds via its At-The-Market Subscription Agreement with Acuity Capital, achieved through the set-off of 4.3 million previously issued shares at a deemed price of $0.28, an 11.1% d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.